Gemma Biotherapeutics, co-founded by James Wilson, MD, PhD, Emeritus Professor of Medicine at Penn Medicine, launched and raised $34 million in a seed round led by Double Point Ventures, Bioluminescence Ventures and Earlybird Venture Capital, with additional backing from Savanne Life Sciences.
The funding will go towards the company’s operational expansion and to help accelerate Gemma Bio’s mission to provide affordable gene therapies to patients with rare diseases. Read more here and here.
Franklin Biolabs, a new genetic medicine focused contract research organization (CRO) also founded by James Wilson, MD, PhD, launched with backing from Savanne Life Sciences which is the investment vehicle of Mauritius-based Bioculture Group. Franklin provides specialty services in immunology, vector production and analytics, next generation sequencing and bioinformatics, and nonclinical pharmacology/toxicology studies. Read more here: